Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas

Neuro-Oncology

Volumn 12, Issue 8, 2010, Pages 799-803

  Hou, Xian Zeng ^a,b   Liu, Wei ^a   Fan, Hai Tao ^a   Liu, Bin ^a   Pang, Bo ^a,b   Xin, Tao ^a   Xu, Shang Chen ^a   Pang, Qi ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

Author keywords

c Met; Hepatocyte growth factor; Pituitary adenoma

Indexed keywords

KI 67 ANTIGEN; SCATTER FACTOR; SCATTER FACTOR RECEPTOR;

ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; ADENOMA; ADULT; BIOSYNTHESIS; FLUORESCENCE IN SITU HYBRIDIZATION; HYPOPHYSIS TUMOR; METABOLISM; MIDDLE AGED; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ADENOMA; ADULT; HEPATOCYTE GROWTH FACTOR; HUMANS; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION, FLUORESCENCE; KI-67 ANTIGEN; MIDDLE AGED; NEOVASCULARIZATION, PATHOLOGIC; PITUITARY NEOPLASMS; PROTO-ONCOGENE PROTEINS C-MET;

EID: 78149486453     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/noq024     Document Type: Article

References (47)

1. Koochekpour S, Jeffers M, Rulong S, et al. Met and hepatocyte growth factor/scatter factor expression in human gliomas. Cancer Res. 1997;57:5391-5398.
2. Moriyama T, Kataoka H, Kawano H, et al. Comparative analysis of expression of hepatocyte growth factor and its receptor, c-met, in gliomas, meningiomas and schwannomas in humans. Cancer Lett. 1998;124:149-155.
3. Arrieta O, Garcia E, Guevara P, et al. Hepatocyte growth factor is associated with poor prognosis of malignant gliomas and is a predictor for recurrence of meningioma. Cancer. 2002;94:3210-3218.
4. Lamszus K, Schmidt NO, Jin L, et al. Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int J Cancer. 1998;75:19-28.
5. Bowers DC, Fan S, Walter KA, et al. Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. 2000;60:4277-4283.
6. Walter KA, Hossain MA, Luddy C, Goel N, Reznik TE, Laterra J. Scatter factor/hepatocyte growth factor stimulation of glioblastoma cell cycle progression through G(1) is c-Myc dependent and independent of p27 suppression, Cdk2 activation, or E2F1-dependent transcription. Mol Cell Biol. 2002;22:2703-2715.
7. Schmidt NO, Westphal M, Hagel C, et al. Levels of vascular endothelial growth factor, hepatocyte growth factor/scatter factor and basic fibroblast growth factor in human gliomas and their relation to angiogenesis. Int J Cancer. 1999;84:10-18.
8. Abounader R, Laterra J. Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis. Neuro-Oncology. 2005;7:436-451.
9. Kim S, Lee B, Kim H, Lee J. Abstracts for the Eighth Congress of the European Association for Neuro-Oncology: Met tyrosine kinase receptor expression in pituitary adenomas. Neuro-Oncology. 2008;10:1134.
10. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer. 1996;77:362-372.
11. Weidner N, Semple JP, Welch WR, Folkman J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N Engl J Med. 1991;324:1-8.
12. Weidner N, Carroll PR, Flax J, Blumenfeld W, Folkman J. Tumor angiogenesis correlates with metastasis in invasive prostate carcinoma. Am J Pathol. 1993;143:401-409.
13. Maeda K, Chung YS, Takatsuka S, et al. Tumor angiogenesis as a predictor of recurrence in gastric carcinoma. J Clin Oncol. 1995;13:477-481.
14. Bochner BH, Cote RJ, Weidner N, et al. Angiogenesis in bladder cancer: relationship between microvessel density and tumor prognosis. J Natl Cancer Inst. 1995;87:1603-1612.
15. Weidner N, Folkman J, Pozza F, et al. Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst. 1992;84:1875-1887.
16. Zhang W, Chu YQ, Ye ZY, Zhao ZS, Tao HQ. Expression of hepatocyte growth factor and basic fibroblast growth factor as prognostic indicators in gastric cancer. Anat Rec (Hoboken). 2009;292:1114-1121.
17. Kuhnen C, Muehlberger T, Honsel M, Tolnay E, Steinau HU, Muller KM. Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density. J Cancer Res Clin Oncol. 2003;129:415-422.
18. Garcia S, Dales JP, Charafe-Jauffret E, et al. Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol. 2007;31:49-58.
19. Strohmeyer D, Strauss F, Rossing C, et al. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res. 2004;24:1797-1804.
20. Puri N, Khramtsov A, Ahmed S, et al. A selective small molecule inhibitor of c-Met. PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts. Cancer Res. 2007;67: 3529-3534.
21. Matsumoto K, Nakamura T. NK4 gene therapy targeting HGF-Met and angiogenesis. Front Biosci. 2008;13:1943-1951.
22. Lamszus K, Laterra J, Westphal M, Rosen EM. Scatter factor/hepatocyte growth factor (SF/HGF) content and function in human gliomas. Int J Dev Neurosci. 1999;17:517-530.
23. Hov H, Tian E, Holien T, et al. c-Met signaling promotes IL-6-induced myeloma cell proliferation. Eur J Haematol. 2009;82:277-287.
24. Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res. 2005;65:9355-9362.
25. Hecht M, Papoutsi M, Tran HD, Wilting J, Schweigerer L. Hepatocyte growth factor/c-Met signaling promotes the progression of experimental human neuroblastomas. Cancer Res. 2004;64:6109-6118.
26. Khoury H, Naujokas MA, Zuo D, et al. HGF converts ErbB2/Neu epithelial morphogenesis to cell invasion. Mol Biol Cell. 2005;16: 550-561.
27. Gallego MI, Bierie B, Hennighausen L. Targeted expression of HGF/SF in mouse mammary epithelium leads to metastatic adenosquamous carcinomas through the activation of multiple signal transduction pathways. Oncogene. 2003;22:8498-8508.
28. Miyata Y, Sagara Y, Kanda S, Hayashi T, Kanetake H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum Pathol. 2009;40:496-504.
29. Garcia S, Dales JP, Charafe-Jauffret E, et al. Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol. 2007;38:830-841.
30. Hida Y, Morita T, Fujita M, et al. Clinical significance of hepatocyte growth factor and c-Met expression in extrahepatic biliary tract cancers. Oncol Rep. 1999;6:1051-1056.
31. Takanami I, Tanana F, Hashizume T, et al. Hepatocyte growth factor and c-Met/hepatocyte growth factor receptor in pulmonary adenocarcinomas: an evaluation of their expression as prognostic markers. Oncology. 1996;53:392-397. (Pubitemid 26283782)
32. Nabeshima K, Shimao Y, Sato S, et al. Expression of c-Met correlates with grade of malignancy in human astrocytic tumours: an immunohistochemical study. Histopathology. 1997;31:436-443.
33. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c-Met expression in glioblastomas. Cancer. 2009;115:140-148.
34. Guerin C, Luddy C, Abounader R, Lal B, Laterra J. Glioma inhibition by HGF/NK2, an antagonist of scatter factor/hepatocyte growth factor. Biochem Biophys Res Commun. 2000;273:287-293.
35. Abounader R, Lal B, Luddy C, et al. In vivo targeting of SF/HGF and c-met expression via U1snRNA/ribozymes inhibits glioma growth and angiogenesis and promotes apoptosis. FASEB J. 2002;16:108-110.
36. Jin H, Yang R, Zheng Z, et al. MetMAb, the one-armed 5D5 anti-c-Met antibody, inhibits orthotopic pancreatic tumor growth and improves survival. Cancer Res. 2008;68:4360-4368.
37. Kontogeorgos G. Predictive markers of pituitary adenoma behavior. Neuroendocrinology. 2006;83:179-188.
38. Gejman R, Swearingen B, Hedley-Whyte ET. Role of Ki-67 proliferation index and p53 expression in predicting progression of pituitary adenomas. Hum Pathol. 2008;39:758-766.
39. Bruna J, Brell M, Ferrer I, Gimenez-Bonafe P, Tortosa A. Ki-67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma. Neuropathology. 2007;27:114-120.
40. Preusser M, Heinzl H, Gelpi E, et al. Ki67 index in intracranial ependymoma: a promising histopathological candidate biomarker. Histopathology. 2008;53:39-47.
41. Wolfsberger S, Fischer I, Hoftberger R, et al. Ki-67 immunolabeling index is an accurate predictor of outcome in patients with intracranial ependymoma. Am J Surg Pathol. 2004;28:914-920.
42. Rodriguez-Pereira C, Suarez-Penaranda JM, Vazquez-Salvado M, et al. Value of MIB-1 labelling index (LI) in gliomas and its correlation with other prognostic factors. A clinicopathologic study. J Neurosurg Sci. 2000;44:203-210.
43. Heegaard S, Sommer HM, Broholm H, Broendstrup O. Proliferating cell nuclear antigen and Ki-67 immunohistochemistry of oligodendrogliomas with special reference to prognosis. Cancer. 1995;76: 1809-1813.
44. Enestrom S, Vavruch L, Franlund B, Nordenskjold B. Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas. Neurochirurgie. 1998;44:25-30.
45. Lo Muzio L, Leonardi R, Mignogna MD, et al. Scatter factor receptor (c-Met) as possible prognostic factor in patients with oral squamous cell carcinoma. Anticancer Res. 2004;24:1063-1069. (Pubitemid 38624939)
46. Chen BK, Ohtsuki Y, Furihata M, et al. Overexpression of c-Met protein in human thyroid tumors correlated with lymph node metastasis and clinicopathologic stage. Pathol Res Pract. 1999;195: 427-433.
47. Sawatsubashi M, Sasatomi E, Mizokami H, Tokunaga O, Shin T. Expression of c-Met in laryngeal carcinoma. Virchows Arch. 1998;432:331-335.